Clinical trial
A Randomized, Double-Blind, Placebo-Controlled MAD Study With Open-Label Extension to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BIIB147 Administered Intrathecally to Adult Participants With ALS
NCT07855211 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled MAD Study With Open-Label Extension to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BIIB147 Administered Intrathecally to Adult Participants With ALS
- Lead sponsor
- Biogen
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- October 22, 2026
- Completion date
- January 23, 2034
- Enrollment
- 69 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.